S&P 500   3,960.07 (+0.66%)
DOW   33,799.44 (+0.60%)
QQQ   283.19 (+0.95%)
AAPL   142.57 (+1.16%)
MSFT   247.02 (+1.08%)
META   115.74 (+1.59%)
GOOGL   94.02 (-0.97%)
AMZN   89.68 (+1.38%)
TSLA   170.17 (-2.22%)
NVDA   167.49 (+3.90%)
NIO   13.16 (+4.61%)
BABA   93.16 (+5.47%)
AMD   70.25 (+0.16%)
T   19.16 (-0.73%)
MU   55.44 (+3.01%)
CGC   3.18 (-1.85%)
F   13.13 (+0.23%)
GE   83.39 (-1.89%)
DIS   92.55 (+0.43%)
AMC   6.19 (+2.31%)
PYPL   75.11 (+0.93%)
PFE   50.97 (+1.45%)
NFLX   306.64 (-0.58%)
S&P 500   3,960.07 (+0.66%)
DOW   33,799.44 (+0.60%)
QQQ   283.19 (+0.95%)
AAPL   142.57 (+1.16%)
MSFT   247.02 (+1.08%)
META   115.74 (+1.59%)
GOOGL   94.02 (-0.97%)
AMZN   89.68 (+1.38%)
TSLA   170.17 (-2.22%)
NVDA   167.49 (+3.90%)
NIO   13.16 (+4.61%)
BABA   93.16 (+5.47%)
AMD   70.25 (+0.16%)
T   19.16 (-0.73%)
MU   55.44 (+3.01%)
CGC   3.18 (-1.85%)
F   13.13 (+0.23%)
GE   83.39 (-1.89%)
DIS   92.55 (+0.43%)
AMC   6.19 (+2.31%)
PYPL   75.11 (+0.93%)
PFE   50.97 (+1.45%)
NFLX   306.64 (-0.58%)
S&P 500   3,960.07 (+0.66%)
DOW   33,799.44 (+0.60%)
QQQ   283.19 (+0.95%)
AAPL   142.57 (+1.16%)
MSFT   247.02 (+1.08%)
META   115.74 (+1.59%)
GOOGL   94.02 (-0.97%)
AMZN   89.68 (+1.38%)
TSLA   170.17 (-2.22%)
NVDA   167.49 (+3.90%)
NIO   13.16 (+4.61%)
BABA   93.16 (+5.47%)
AMD   70.25 (+0.16%)
T   19.16 (-0.73%)
MU   55.44 (+3.01%)
CGC   3.18 (-1.85%)
F   13.13 (+0.23%)
GE   83.39 (-1.89%)
DIS   92.55 (+0.43%)
AMC   6.19 (+2.31%)
PYPL   75.11 (+0.93%)
PFE   50.97 (+1.45%)
NFLX   306.64 (-0.58%)
S&P 500   3,960.07 (+0.66%)
DOW   33,799.44 (+0.60%)
QQQ   283.19 (+0.95%)
AAPL   142.57 (+1.16%)
MSFT   247.02 (+1.08%)
META   115.74 (+1.59%)
GOOGL   94.02 (-0.97%)
AMZN   89.68 (+1.38%)
TSLA   170.17 (-2.22%)
NVDA   167.49 (+3.90%)
NIO   13.16 (+4.61%)
BABA   93.16 (+5.47%)
AMD   70.25 (+0.16%)
T   19.16 (-0.73%)
MU   55.44 (+3.01%)
CGC   3.18 (-1.85%)
F   13.13 (+0.23%)
GE   83.39 (-1.89%)
DIS   92.55 (+0.43%)
AMC   6.19 (+2.31%)
PYPL   75.11 (+0.93%)
PFE   50.97 (+1.45%)
NFLX   306.64 (-0.58%)
LON:AGY

Allergy Therapeutics - AGY Share Forecast, Price & News

GBX 11.72
-1.53 (-11.55%)
(As of 12/8/2022 04:11 PM ET)
Add
Compare
Today's Range
11.12
12.70
50-Day Range
13
20
52-Week Range
11.12
35
Volume
315,024 shs
Average Volume
112,571 shs
Market Capitalization
£79.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AGY stock logo

About Allergy Therapeutics (LON:AGY) Stock

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

Receive AGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGY Stock News Headlines

Allergy Therapeutics Names Martin Hopcroft Interim CFO - Quick Facts
Allergy Therapeutics to resume UK production in mid-November
Allergy Therapeutics says CFO to leave
Allergy Therapeutics : Result of AGM
Allergy Therapeutics : Director Dealings
See More Headlines
Receive AGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGY Company Calendar

Last Earnings
3/04/2020
Today
12/08/2022

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
600
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£72.77 million
Cash Flow
GBX 2.83 per share
Book Value
GBX 6 per share

Miscellaneous

Free Float
N/A
Market Cap
£79.58 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Manuel Llobet (Age 58)
    CEO & Exec. Director
    Comp: $559.22k
  • Mr. Nicolas Alexander Ulrich Wykeman (Age 57)
    CFO & Exec. Director
    Comp: $312.15k
  • Ms. Beverly Lees
    Group Operations Director
  • Dr. Murray Skinner
    Chief Scientific Officer
  • Mr. Santiago Puig
    Bus. Devel. Director
  • Ms. Sue Baker
    Head of HR
  • Simon Piggott
    Head of Clinical Science
  • Alan Bullimore
    Head of Communication & Market Devel.
  • Mr. Russell Picket
    Group Financial Controller
  • Sara Goldsbrough
    Company Sec.













AGY Stock - Frequently Asked Questions

How have AGY shares performed in 2022?

Allergy Therapeutics' stock was trading at GBX 32.25 at the start of the year. Since then, AGY stock has decreased by 62.8% and is now trading at GBX 12.
View the best growth stocks for 2022 here
.

How were Allergy Therapeutics' earnings last quarter?

Allergy Therapeutics plc (LON:AGY) released its quarterly earnings results on Wednesday, March, 4th. The company reported $2.40 earnings per share for the quarter.

What other stocks do shareholders of Allergy Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergy Therapeutics investors own include (RLYP) (RLYP), Royalty Pharma (RPRX), Verastem (VSTM), Berkeley Energia (BKY), Burford Capital (BUR), Direxion Daily Gold Miners Index Bear 2x Shares (DUST), Flowtech Fluidpower (FLO), Merrimack Pharmaceuticals (MACK) and Shanta Gold (SHG).

What is Allergy Therapeutics' stock symbol?

Allergy Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AGY."

How do I buy shares of Allergy Therapeutics?

Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Allergy Therapeutics' stock price today?

One share of AGY stock can currently be purchased for approximately GBX 12.

How much money does Allergy Therapeutics make?

Allergy Therapeutics (LON:AGY) has a market capitalization of £81.49 million and generates £72.77 million in revenue each year.

How many employees does Allergy Therapeutics have?

The company employs 600 workers across the globe.

How can I contact Allergy Therapeutics?

Allergy Therapeutics' mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The official website for the company is www.allergytherapeutics.com. The company can be reached via phone at +44-1903-844700.

This page (LON:AGY) was last updated on 12/8/2022 by MarketBeat.com Staff